Markets:

Overview

News

Currencies

International

Treasuries

Atai Beckley N.V - Common Shares (NQ:ATAI)

4.356 -0.044 (-1.00%)

Streaming Delayed Price Updated: 3:27 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atai Beckley N.V - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday ↗

April 03, 2024

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

Via Benzinga

Topics Stocks

March Recap: Largest Psychedelic Drug Stocks Up Another 5% ↗

March 30, 2024

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.

Via Talk Markets

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline ↗

March 29, 2024

Via Benzinga

Recap: ATAI Life Sciences Q4 Earnings ↗

March 28, 2024

Via Benzinga

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression ↗

March 28, 2024

Via Benzinga

ATAI Stock Earnings: ATAI Life Sciences Beats EPS, Misses Revenue for Q4 2023 ↗

March 28, 2024

ATAI stock results show that ATAI Life Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

March 28, 2024

From atai Life Sciences

Via GlobeNewswire

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

March 27, 2024

From atai Life Sciences

Via GlobeNewswire

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗

March 20, 2024

Via Benzinga

Topics Economy

The Next Great Biotech Boom Has Arrived

March 19, 2024

EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review ↗

March 16, 2024

Via Benzinga

Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week ↗

March 11, 2024

The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder.

Via Talk Markets

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗

March 04, 2024

Via Benzinga

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

March 04, 2024

From atai Life Sciences

Via GlobeNewswire

Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD ↗

March 01, 2024

The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.

Via Talk Markets

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

February 28, 2024

From atai Life Sciences

Via GlobeNewswire

Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex ↗

February 18, 2024

IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...

Via Talk Markets

Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More ↗

February 15, 2024

Via Benzinga

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

February 06, 2024

From atai Life Sciences

Via GlobeNewswire

5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week ↗

January 30, 2024

The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.

Via Talk Markets

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More ↗

January 15, 2024

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.

Via Benzinga

5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week ↗

January 13, 2024

The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.

Via Talk Markets

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

January 24, 2024

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

Via FinancialNewsMedia

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗

January 12, 2024

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Via Benzinga

Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution ↗

January 09, 2024

Psychedelic stocks have been making big moves beneath the surface, and the sector's popularity might spark again in 2024.

Via InvestorPlace

3 Big New Catalysts for Psychedelics Stocks in 2024 ↗

January 08, 2024

This could be the year that psychedelics stocks start to fly.

Via The Motley Fool

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗

January 07, 2024

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.